catalent glp 1 Novo's deal is great for GLP-1s. But what about drug manufacturing? GLP-1 drug shortages create US
Description
What this means for food R&D.
It is currently in Phase 2 clinical trials for the treatment of overweight and obesity
The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.
Were excited to partner with WTW as the sustainable weight-loss and responsible prescribing solution powering their new Rx Direct Access program for GLP-1 access and affordability
It assists in maintaining carbohydrate stability already in a normal range, helping to optimize fat metabolism and cellular energy production Appetite Suppressant & Craving Control: Stop food noise in its tracks
GLP-1
